Publications
- The translocation t(2;11)(p21;q23) without MLL gene rearrangement-a possible marker of good prognosis in myelodysplastic syndrome patients2014 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Notes to the pathophysiology of myelodysplastic syndrome, demethylation therapy and the role of cytokine-induced differentiation2013 | First Faculty of Medicine
- Myelodysplastic syndromes – therapy progress over the last two decades2013 | First Faculty of Medicine
- Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II2013 | First Faculty of Medicine
- Immunomodulation therapy - lenalidomide in the treatment of myelodysplastic syndrome in low-risk groups with deletion of the long arm of chromosome 52013 | First Faculty of Medicine
- TP53 mutations in myelodysplastic syndrome is significantly correlated with deletion of the long arm 5.chromozomu (5q-) and usually has a negative prognostic value (meaning TP53 examination in the era of lenalidomide)2013 | First Faculty of Medicine
- Current recommendations in chelation therapy2013 | First Faculty of Medicine
- Treatment of patients with myelodysplastic syndrome with iron overload oral chelator deferasirox2013 | First Faculty of Medicine
- Deferasirox in patients with myelodysplastic syndrome and iron overload - Results of the EPIC study - Commenting on the study2013 | First Faculty of Medicine
- A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes2013 | Publication without faculty affiliation
Loading network view...